Seroatlas · Human Serome Atlas

RRAS

Ras-related protein R-Ras

Also known as: R-Ras, RRAS_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P10301
Gene: RRAS
Ensembl: ENSG00000126458
Chromosome: 19
Canonical length: 218 aa
Protein class: Predicted intracellular proteins, RAS pathway related proteins
Subcellular location: Vesicles

OverviewNCBI Gene

The protein encoded by this gene is a small GTPase involved in diverse processes including angiogenesis, vascular homeostasis and regeneration, cell adhesion, and neuronal axon guidance. Mutations in this gene are found in many invasive cancers. [provided by RefSeq, Jul 2015]

Canonical amino-acid sequenceUniProt

218 residues, UniProt reviewed canonical sequence.

>P10301|RRAS
     1  MSSGAASGTG RGRPRGGGPG PGDPPPSETH KLVVVGGGGV GKSALTIQFI QSYFVSDYDP
    61  TIEDSYTKIC SVDGIPARLD ILDTAGQEEF GAMREQYMRA GHGFLLVFAI NDRQSFNEVG
   121  KLFTQILRVK DRDDFPVVLV GNKADLESQR QVPRSEASAF GASHHVAYFE ASAKLRLNVD
   181  EAFEQLVRAV RKYQEQELPP SPPSAPRKKG GGCPCVLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RRAS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 477 nTPM

Expression across tissuesHPA

Tissue

blood vessel: 477 nTPM
colon: 250 nTPM
heart muscle: 210 nTPM
urinary bladder: 188 nTPM
endometrium: 187 nTPM
lung: 173 nTPM

Single-cell type

vascular smooth muscle cells: 276 nCPM
decidual stromal cells: 243 nCPM
smooth muscle cells: 218 nCPM
alveolar cells type 1: 164 nCPM
pericytes: 145 nCPM
breast lactating cells: 139 nCPM

Immune cell

non-classical monocyte: 25 nTPM
intermediate monocyte: 21 nTPM
classical monocyte: 5.4 nTPM
myeloid DC: 3.7 nTPM
total PBMC: 2.2 nTPM
memory B-cell: 2 nTPM

Brain region

thalamus: 29 nTPM
medulla oblongata: 28 nTPM
hypothalamus: 27 nTPM
pons: 23 nTPM
spinal cord: 23 nTPM
basal ganglia: 21 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about RRAS.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 366 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Inborn genetic diseases

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.1
gnomAD pLI: 0
gnomAD missense Z: 0.68
DepMap mean gene effect: 0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RRAS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RRAS as an antibody target. Whether an autoantibody or antibody against RRAS could matter depends on whether native RRAS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RRAS is annotated at the cell surface, where native RRAS is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label RRAS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...